Press Releases_Guangzhou BeBetter Medicine Technology Co, LTD.

Current Position：Home Page > Press Releases

BEBT-503 Passes Phase I Clinical Trial in Australia, Marking a Milestone in BeBetter Med's Global Collaboration Efforts

2023-10-31

Recently, BeBetter MedInc. successfully completed the Phase I clinical trial of BEBT-503in Australia. BEBT-503 is a pan-PPAR agonist developed by BebetterMed, boasting exclusive global intellectual property rights. The trial was a randomized, double-blind

BeBetter Med’s Pan-mutant EGFR Inhibitor BEBT-109 Phase III Clinical Trial Application is Approved by CDE

2023-10-16

Recently, the pan-mutant EGFR inhibitor BEBT-109, developed by BeBetter Med Inc., has received approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration in Chinato conduct a confirmatory Phase III clinical trial fo

BeBetter Med’s First-in-Class New Drug BEBT-908 NDA Accepted

2023-10-09

On October 8, 2023, the New Drug Application (NDA) ofBEBT-908, a class I newdrug independently developed byBeBetter Med Inc.has been officially accepted by the China National Medical Products Administration's Center for Drug Evaluation (CDE). This d

BeBetter Med Inc. successfully holds the sponsors meeting & the first general meeting of shareholders

2021-12-22

The sponsors meeting & the first general meeting of shareholders was successfully held at the company headquarters on December 20, 2021. With the approval of all sponsors, the company was reconstructed from ‘Guangzhou BeBetter Medicine Technology Co

BeBetter Med’s BEBT-209 Approved for Phase III Clinical Trials

2021-12-20

On December 18, 2021, the National Center for Drug Evaluation (CDE) approved Guangzhou BeBetter Med Inc. to develop BEBT-209 combined with Fulvestrantin the treatment of HR+/HER2- advanced breast cancer III Phase III clinical trial, titled "BEBT-209

First-In-Class Drug RGRN-305 (BEBT-305) Clinical Proof-of-Concept Study Results Published in British Journal of Dermatology

2021-11-24

The executive director of the International Psoriasis Associationand Professor Las Iversen’s team from Denmark published "HSP90 inhibitor RGRN-305 for oral treatment of plaque type psoriasis: efficacy, safety and biomarker results in an open-label

First-In-Class Drug BEBT-908 Research Results of BEBT-908 Published on CANCER RESEARCH

2021-11-06

The research outcomes of our company’s First-In-Class drug BEBT-908 have been published as a research paper "A Dual PI3K/HDAC Inhibitor Induces Immunogenic Ferroptosis to Potentiate Cancer Immune Checkpoint Therapy" (PI3K/HDAC dual-target inhi

BeBetter Med’s BEBT-908 granted Breakthrough Therapy designation

2021-10-13

On October 13,2021, the Center for Drug Evaluation (CDE) of has granted BeBetter Med’s BEBT-908 "Breakthrough Therapy " designation, which is used for the treatment of patients after at least two systemic treatments of relapsed or refractory

BeBetter Med Inc. Receives Two New Clinical Approvals to Evaluate the Safety and Efficacy of New Drug Combination Treatment for Two Malignancies Resistant to Multiple Lines of Therapy

2021-09-29

Recently, BeBetter Med’s application of clinical trials for "BEBT-109 combined with BEBT-908 for the treatment of advanced NSCLC that is resistant to third-generation EGFR inhibitor therapy" and "BEBT-209 combined with BEBT-908 for the t